Download press release.

Gabather will present the development of its drug development programs (CNS) at the European Smallcap Event in Paris Aril 11-12. The event is primarily directed towards accredited and institutional investors.

Gabather has a comparably large number of shareholders which results in a good liquidity in daily trading of the stock, GABA (Aktietorget, SE). The company is aiming to attract international institutional investors to strengthen the support for its long term drug development efforts in the field of Central Nervous System (CNS) based diseases. Gabather is presenting to investors on Monday April 11th and will have several one to one meetings on Tuesday.

Gabather CEO  Bert Junno comments: “Gabather wishes to attract new international institutional and private shareholders. The European Smallcap Event is a very good event to present and meet new prospective owners..”

Gabather AB
Bert Junno, CEO
E-mail: bj@gabather.com

Gabather AB
Gabather was founded in 2014 as a result of more than ten years of collaborative research between Lund University (Sweden) and the Research Institute of Biological Chemistry in Roskilde (Denmark). The aim of the company is to develop novel small molecule drugs to treat diseases with an origin in the central nervous system. Gabather founders are the Forskarpatent fund together with scientists Olov Sterner and Mogens Nielsen..

Disclaimer
This press release contains forward looking information including subjective statements that are prognoses of future developments. The forward looking statements are only valid on the date they are made and are like research and development of biotechnical products, high risk activities. With this in mind acual outcome may differ considerably from what is described in this press release.